close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allogene Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Appoints Earl Douglas as General Counsel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today